{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T14:40:11Z","timestamp":1741704011919,"version":"3.38.0"},"reference-count":31,"publisher":"ALUNA","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>Aim: To systematize and comprehensively analyze scientific sources and studies on metabolic-associated steatotic liver disease (MASLD) based on materials from the European Congress of the European Association for the Study of the Liver (EASL \u2013 2024).\nMaterials and Methods: This paper analyzes the current scientific research on the prevalence, pathogenesis, diagnostic methods, prognosis, and pharmacotherapy of MASLD presented at the EASL 2024 Congress. The following methods were used in the preparation of the work: a systematic approach and bibliosemantic analysis.\nConclusions: Studies on the pathogenesis of MASLD progression confirm the significant role of insulin resistance and hyperinsulinemia in increasing hepatocyte cytolysis activity, raising the concentration of cytokeratin CK-18, HbA1c, low-density lipoproteins, triglycerides, and the severity of fibrosis (FIB-4). EASL 2024 studies evaluated the diagnostic efficiency of non-invasive methods for assessing steatosis and liver fibrosis severity in MASLD (FIB-4, FibroScan\u00ae, Enhanced Liver Fibrosis (ELF), Vibration Controlled Transient Elastography (VCTE), LiverPRO, etc.). Due to the high prevalence of steatotic liver disease, comorbidities such as chronic viral hepatitis C, autoimmune hepatitis, and alcoholic liver disease \u2013 contributing to liver fibrosis progression and hepatocellular carcinoma \u2013 are significant. Promising drugs for MASLD treatment include resmethyrom, fibroblast growth factor 21 analogs (including pegosafermin), and pemvidutide, a long-acting, balanced GLP-1\/glucagon dual receptor agonist.<\/jats:p>","DOI":"10.36740\/merkur202501117","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:58:21Z","timestamp":1741701501000},"page":"120-125","source":"Crossref","is-referenced-by-count":0,"title":["Current priorities in research on metabolic-associated fatty liver disease based on the results of EASL \u2013 2024"],"prefix":"10.36740","volume":"53","author":[{"given":"Leonid L.","family":"Pinsky","sequence":"first","affiliation":[{"name":"BOGOMOLETS NATIONAL MEDICAL UNIVERSITY, KYIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mykola V.","family":"Khaitovych","sequence":"additional","affiliation":[{"name":"BOGOMOLETS NATIONAL MEDICAL UNIVERSITY, KYIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga A.","family":"Golubovska","sequence":"additional","affiliation":[{"name":"BOGOMOLETS NATIONAL MEDICAL UNIVERSITY, KYIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina P.","family":"Ryzhova","sequence":"additional","affiliation":[{"name":"BOGOMOLETS NATIONAL MEDICAL UNIVERSITY, KYIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Abstract Book of EASL Congress 2024 (5-8 June 2024, Milan, Italy). J Hepatol. 2024;80:S1-S940. doi:10.1016\/S0168-8278(24)00433-1.","DOI":"10.1016\/S0168-8278(24)00238-1"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Anirvan P, Khatua CR, Nath P et al. Temporal trends in the profile of non-alcoholic fatty liver disease: a decadal experience. J Hepatol. 2024;80(S1):S488. doi:10.1016\/S0168-8278(24)01491-0.","DOI":"10.1016\/s0168-8278(24)01491-0"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Younossi Z, Lazarus JV, Allene AM et al. Cost of inaction for metabolic dysfunction-associated steatohepatitis (MASH): the projected economic burden in the United States. J Hepatol. 2024;80(S1):S470. doi:10.1016\/S0168-8278(24)01451-X.","DOI":"10.1016\/s0168-8278(24)01451-x"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Alqahtani S, Alswat KA, Mawardi M et al. Stigma in steatotic liver disease (SLD): a survey of patients from Saudi Arabia. J Hepatol. 2024;80(S1):S496. doi:10.4103\/sjg.sjg_122_24.","DOI":"10.1016\/s0168-8278(24)01512-5"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Ratziu V, Schattenberg JM, Alkhouri N et al. Insulin resistance as an independent predictor of metabolic dysfunction-associated steatohepatitis (MASH) severity: combined data from multiple therapeutic trials including more than 10, 000 patients. J Hepatol. 2024;80(S1): S464. doi:10.1016\/S0168-8278(24)01437-5.","DOI":"10.1016\/s0168-8278(24)01437-5"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Ekelik M, G\u00f6k\u00e7e DT, Gumussoy M et al. Histological and clinical disease progression in patients with metabolic dysfunction-associated steatotic liver disease using paired liver biopsy. J Hepatol. 2024;80(S1):S479. doi:10.1016\/S0168-8278(24)01469-7.","DOI":"10.1016\/s0168-8278(24)01469-7"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Sato S, Kawai H, Takuya G et al. Steatotic liver disease with normal liver enzyme: clinical use of ultrasound attenuation method and share wave elastography. J Hepatol. 2024;80(S1):S490. doi:10.1016\/S0168-8278(24)01497-1.","DOI":"10.1016\/s0168-8278(24)01497-1"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Caussy C, Verge\u0300s B, Damien L et al. Diagnostic performance of non-invasive tests and comparison of AGA and EASL algorithm for the screening of MASLDrelated advanced fibrosis in diabetes and nutrition clinics. J Hepatol. 2024;80(S1):S508. doi:10.1016\/S0168-8278(24)01539-3.","DOI":"10.1016\/s0168-8278(24)01539-3"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Kawata K, Takahashi H, Arai T et al. The performance of the enhanced liver fibrosis test by cardiometabolic risk factors in patients with metabolic dysfunctionassociated steatotic liver disease. J Hepatol. 2024;80(S1):S537. doi:10.1016\/S0168-8278(24)01606-4.","DOI":"10.1016\/s0168-8278(24)01606-4"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Loomba R, Alkhouri N, Noureddin M et al. Paired assessment of enhanced liver fibrosis (ELF) and fibrosis-4 (FIB-4) scores is associated with an elevated risk of liver-related clinical events in participants with advanced fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). J Hepatol. 2024;80(S1):S505. doi:10.1016\/S0168-8278(24)01532-0.","DOI":"10.1016\/s0168-8278(24)01532-0"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Lindvig K, Alkhouri N, Nadeem R et al. Optimizing MASLD trial recruitment: LiverPRO vs. FIB-4 in reducing false positives and unnecessary biopsies. J Hepatol. 2024;80(S1):S510. doi:10.1016\/S0168-8278(24)01544-7.","DOI":"10.1016\/s0168-8278(24)01544-7"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Noureddin M, Jeannin S, Alkhouri N et al. Clinical and biological predictors of liver fat content \u22658% as assessed by MRI-PDFF: combined data from multiple therapeutic trials including more than 10, 000 patients. J Hepatol. 2024;80(S1):S518. doi:10.1016\/S0168-8278(24)01564-2.","DOI":"10.1016\/s0168-8278(24)01564-2"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Rowe I, Farzi M, McGenity C et al. The true diagnostic performance of magnetic resonance elastography for the detection of advanced fibrosis in metabolic dysfunctionassociated steatotic liver disease exceeds the diagnostic performance of liver biopsy. J Hepatol. 2024;80(S1):S530. doi:10.1016\/S0168-8278(24)01589-7.","DOI":"10.1016\/s0168-8278(24)01589-7"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Berberova M, Nikolov P, Kumar D et al. Metabolic dysfunction associated steatohepatitis (MASH) disease progression phenotyping features based on medical claims. J Hepatol. 2024;80(S1):S485. doi:10.1016\/S0168-8278(24)01484-3.","DOI":"10.1016\/s0168-8278(24)01484-3"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Kim SU, Lee JS, Kim MN et al. Increased risk of mortality in metabolic dysfunction-associated steatotic liver disease: a nationwide population-based cohort study. J Hepatol. 2024;80(S1):S495-S496. doi:10.1016\/S0168-8278(24)01510-1.","DOI":"10.1016\/s0168-8278(24)01510-1"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Song SJ, Wong VW, Wong GL et al. An inference model of risk factors for liver-related complications among patients with type 2 diabetes mellitus. J Hepatol. 2024;80(S1):S479. doi:10.1016\/S0168-8278(24)01470-3.","DOI":"10.1016\/s0168-8278(24)01470-3"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Ayonrinde O, Adams L, Zelesco M et al. Severity of hepatic steatosis measured with controlled attenuation parameter as a determinant of carotid atherosclerosis in the Raine Study. J Hepatol. 2024;80(S1):S487. doi:10.1016\/S0168-8278(24)01490-9.","DOI":"10.1016\/s0168-8278(24)01490-9"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Campo NP, Ferro A, Castelnuovo G et al. Hepatic steatosis contributes to cognitive impairment in patients with metabolic dysfunction-associated steatotic liver disease and\/or type 2 diabetes-mellitus. J Hepatol. 2024;80(S1):S483. doi:10.1016\/S0168-8278(24)01480-6.","DOI":"10.1016\/s0168-8278(24)01480-6"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Koutny F, Aigner E, Datz C et al. Depression as a determinant of metabolic dysfunction-associated steatotic liver disease (MASLD) risk in the Paracelsus 10,000 study. J Hepatol. 2024;80(S1):S500. doi:10.1016\/S0168-8278(24)01521-6.","DOI":"10.1016\/s0168-8278(24)01521-6"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Shih PT, Shih CI, Wu KT et al. Hepatitis C infection increases the risk of new-onset HTN and DM among patients with metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024;80(S1):S490. doi:10.1016\/S0168-8278(24)01496-X.","DOI":"10.1016\/s0168-8278(24)01496-x"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Soria A, D\u00edaz A, Iruzubieta P et al. The presence of autoimmune characteristics in metabolic associated steatosis liver disease patients increases the risk of liver disease progression. Study from the multicentric spanish register (HEPAMET). J Hepatol. 2024;80(S1):S468. doi:10.1016\/S0168-8278(24)01447-8.","DOI":"10.1016\/s0168-8278(24)01447-8"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Marti-Aguado D, Panero JL, Gomez EV et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in subjects with metabolic dysfunctionassociated steatotic liver disease. J Hepatol. 2024;80(S1):S469. doi:10.1016\/j.jhep.2024.06.036.","DOI":"10.1016\/s0168-8278(24)01448-x"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Duseja AK, Mehta M, De A et al. Compared to complete abstainers, non-significant alcohol use may be associated with more severe liver disease in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) \u2013 The multicentre study of the indian consortium on MASLD. J Hepatol. 2024;80(S1):S476. doi:10.1016\/S0168-8278(24)01462-4.","DOI":"10.1016\/s0168-8278(24)01462-4"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Liew IY, Phua HP, Lim WY et al. Risk factors for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024;80(S1):S497-S498. doi:10.1016\/S0168-8278(24)01515-0.","DOI":"10.1016\/s0168-8278(24)01515-0"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Park Y, Jung J, Kim Gi-Ae. Increased risk of cancers in metabolic dysfunction-associated steatotic liver disease and MetALD. J Hepatol. 2024;80(S1):S468. doi:10.1016\/S0168-8278(24)01446-6.","DOI":"10.1016\/s0168-8278(24)01446-6"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Veldhuis SO, Drossaert S, Ouden MD et al. Barriers and motivators for implementation of lifestyle changes in a large population with MASLD. EMJ Hepatol. 2024;12(1):42-43. doi:10.33590\/emjhepatol\/DFOF9828.","DOI":"10.33590\/emjhepatol\/dfof9828"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Robertson T, Hamdan N, Bera C et al. Association between liver fibrosis, mental health, and lifestyle behaviors in patients with Metabolic Dysfunction- Associated Steatotic Liver Disease. J Hepatol. 2024;80(S1):S497. doi:10.1016\/S0168-8278(24)01513-7.","DOI":"10.1016\/s0168-8278(24)01513-7"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Song SJ, Wong VW, Wong GL. Impact of antidiabetic medications on adverse liver outcomes in patients with type 2 diabetes mellitus: independent and interactive effects. J Hepatol. 2024;80(S1):S475. doi:10.1016\/S0168-8278(24)01460-0.","DOI":"10.1016\/s0168-8278(24)01460-0"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Lee HA, Kim HY, Seo YS et al. Effect of antidiabetics on the risk of hepatocellular carcinoma in patients with diabetes and metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024;80(S1):S481. doi:10.1016\/S0168-8278(24)01475-2.","DOI":"10.1016\/s0168-8278(24)01475-2"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. J\u00f6rn S, Rohit L, Rebecca T et al. Assessment of resmetirom efficacy (80 mg vs. 100 mg) stratified by baseline body mass index and weight in patients from the MAESTRO-NASH trial. The American Journal of Gastroenterology. 2024;119(10S):S1217-S1217. doi:10.14309\/01.ajg.0001036044.63596.59.","DOI":"10.14309\/01.ajg.0001036044.63596.59"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Loomba R, Abdelmalek MF, Kowdley KV et al. Week 48 results from the phase 2b ENLIVEN extension study investigating pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis. J Hepatol. 2024;80(S1):S72. doi:10.1016\/S0168-8278(24)00559-2.","DOI":"10.1016\/s0168-8278(24)00559-2"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:58:45Z","timestamp":1741701525000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2025i1net.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202501117","archive":["Internet Archive"],"relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}